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Abstract
Background: An intrathecal polyspecific antibody response is a well known finding in multiple
sclerosis. However, little is known about the evolution of intrathecal antibodies over time and their
impact on the disease progress. Therefore, we focused in this study on the intrathecal polyspecific
antibody response in multiple sclerosis.
Methods: Here we present a follow-up study of 70 patients with multiple sclerosis over 1 to 106
months. Serum and cerebrospinal fluid sample pairs were obtained from 1 to 5 consecutive lumbar
punctures. CSF cell count, the IgG index, local IgG synthesis, oligoclonal bands and the antibody
index for measles, rubella or varicella zoster were calculated. Results were analysed with regard to
clinical characteristics of the patients.
Results: Once an intrathecal antibody response was established, it persisted. De novo antibody
response against measles virus developed in 7% of the patients between the first and the second
spinal tap. In two of seven patients where 5 consecutive CSF samples were available, the intrathecal
antibody response expanded from one to three antigens. Furthermore, an intrathecal measles
antibody production was associated with a rapid progression of the disease.
Conclusion: These data stress the importance of activated B cells for the disease process and the
clinical outcome in multiple sclerosis.
Background
An elevated immunoglobulin G (IgG) index and the pres-
ence of oligoclonal bands (OCB) in the cerebrospinal
fluid (CSF) are a hallmark of multiple sclerosis (MS) [1,2].
Although this finding is not specific for MS, 72 % percent
of patients present with an elevated IgG index and even 98
% show an oligoclonal distribution of IgG bands exclu-
sively in the CSF [3,4]. Intrathecal IgG is thought to be the
product of B lymphocytes residing in the brain of MS
patients after they have crossed the blood brain barrier in
an activated state with the help of various co-stimulatory
signals [5]. Instead of undergoing apoptosis, the B cells
expand clonally within the central nervous system (CNS)
giving rise to a persistent antibody production [6]. Despite
intense investigations, no single antigen against which the
antibodies might be directed has been isolated so far. In
contrast, the intrathecal antibody response covers a large
number of CNS and non-CNS antigens as well as various
pathogens [7-14], including the viral antigens such as
measles, rubella and varicella zoster [15]. In up to 96 % of
MS patients an intrathecal antibody production against at
least one of the three antigens has been found [3,16].
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Little is known, however, about the clinical significance of
these findings. Previous studies attempting to evaluate the
long-term evolution of intrathecal viral antibodies were
hampered by technical shortcomings such as few sensitive
detection methods and an absence of correction for
blood-CSF-barrier disturbance [17,18]. Hence, the find-
ings of these preliminary studies were partially contradic-
tory with regard to the stability of the CSF antibody
production [17,18]. Furthermore, no correlation to the
clinical course could be demonstrated [17,18]. Here we
report the results of a follow-up study on 70 MS patients
from which at least two CSF analyses including cell count,
IgG index, local IgG synthesis, antibody specific index and
oligoclonal bands were available. The clinical implica-
tions of the immunological findings are discussed.
Methods
Patients
The study used 70 consecutive patients with definite MS
according to the criteria of Poser [19] and a primary
relapsing course. All patients had at least two spinal taps,
mostly during disease exacerbations. Three lumbar punc-
tures (LP) were performed in 26 patients, four in 12
patients and five in 7 patients. Patients were characterized
clinically by age, sex, disease duration, course of the dis-
ease and the expanded disability status scale (EDSS), doc-
umented at the time of the first LP. Furthermore, the
progression index was calculated as the ratio of the EDSS
and the disease duration for each patient. Patients with
corticosteroid treatment in the last four weeks or with
immunomodulatory or immunosuppressive therapy in
the last 3 months prior to the first LP were excluded. Cer-
ebrospinal fluid and serum sample pairs were analyzed
for cell count in the CSF, oligoclonal bands in serum and
CSF, local IgG synthesis, IgG index and antibody index for
the following antigens: measles, rubella and varicella
zoster virus. We focused only on these specific antigens
because of the frequent detection of these antigens within
CSF in the case of MS described in prior studies [3].
Cell count
The CSF cell count was determined immediately after LP.
For this purpose, 90 µl of CSF were stained with 10 µl dye
containing 20% crystal violet solution, 20 % glacial acetic
acid and 60% H2O. Cells were enumerated in a Fuchs-
Rosenthal counting chamber.
IgG index
The intrathecal IgG production was quantitated by the IgG
index. For this purpose, albumin and IgG were measured
in matched serum and CSF pairs by nephelometry accord-
ing to the manufacturer's instructions using commercially
available kits (antiserum against human albumin or IgG,
respectively) and the BN 100 nephelometer (both Dade
Behring GmbH, Marburg, Germany). The IgG index was
calculated according to the following formula: (CSF IgG ×
serum albumin) / (serum IgG × CSF albumin). An IgG
index above 0.7 was indicative of an intrathecal IgG syn-
thesis [20].
Local IgG synthesis
We quantitated the local IgG synthesis within the CSF
with the help of a method described by Reiber and col-
leagues [3]. Therefore, we used the following formula:
Igloc = [QIg - Qlim (Ig)] × Ig(serum) (Q = quotient CSF:
serum). Details of the calculation have been described
previously [21].
Oligoclonal bands (OCB)
All samples were analyzed directly after performing the LP
without freezing, to minimize post-sampling changes.
The presence of oligoclonal bands in the CSF indicated an
intrathecal IgG production. For detection of OCB, isoelec-
tric focusing was performed on matched serum and CSF
sample pairs. The serum and CSF samples were diluted to
the same IgG concentration and run on polyacrylamide
gel precoated with ampholytes (pH between 4.5 and
10.0) at increasing voltage according to the manufac-
turer's instructions (Servalyt Precotes, Serva Electrophore-
sis GmbH, Heidelberg, Germany). Subsequently, a silver
staining with commercially available reagents was done as
indicated by the manufacturer (Serva Electrophoresis
GmbH). The patterns were interpreted qualitatively by
comparing the presence or absence of OCB in the serum
and CSF.
Antibody specific index (AI)
During the whole study period, antibody production
against measles, rubella and varicella zoster virus was ana-
lysed in matched serum and CSF pairs by commercially
available, specific enzyme immune assays (Enzygnost by
Dade Behring) on an ELISA II processor using the alpha-
method (Dade Behring). The AI was calculated according
to the following formula: AI = Q spec. / Q lim. with Q
spec. = CSF antibodies / serum antibodies and Q lim.
being calculated from the CSF / serum albumin ratio
according to the Reiber formula [21]. AI larger than 1.4
indicate an intrathecal antibody synthesis against the
given antigen.
Statistical analyses
This study was carried out as retrospective case-control
study. The mean values of cell count, IgG index, local IgG
synthesis and AI were compared for the whole group at
the different time points (LP 1 to 5) by non-parametric
tests for dependent samples (Friedman test). The percent-
age of patients positive for OCB or with a positive AI
against measles at the 1st and 2nd LP, respectively, was
compared with the Fisher's Exact test.Cerebrospinal Fluid Research 2005, 2:3 http://www.cerebrospinalfluidresearch.com/content/2/1/3
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Different clinical subgroups, i.e. those with a high or low
EDSS, were analyzed for their mean measles AI with the
help of a median split. The mean measles AI in the sub-
groups was compared with a non-parametric test for inde-
pendent samples (Mann Whitney U test).
Results
Patient characteristics
A total of 70 patients, 45 women and 25 men, were
included in this study. The mean age of the patients was
38 years (range 21 to 67 years). All patients had a primary
relapsing course of the disease. The mean disease duration
was 4.5 years with a range of one to 37 years. The mean
EDSS at study entry was 2.9 (standard deviation SD 1.33).
The mean time from the first LP to the second was 15
months with a range from 1 to 81 months. The mean time
from the first to the last LP was 22 months (range: 1 to
106 months) in all patients. In 30 patients the range
between the first and second LP was at least 12 months. In
24 patients the time between these LPs was less than 6
months. At the occasion of the second LP, 22 patients
received an immunomodulatory or immunosuppressive
treatment (interferon beta, glatiramer acetate, intravenous
immunoglobulin, azathioprine). It has to be stressed that
the study population is inhomogeneous. If the LPs were
sorted by the follow-up years in which they had been
arranged, no new information could be observed. This
might be due to the wide range of time between the differ-
ent LPs in this patient cohort (1 to 106 months). The data
are not shown.
Mean IgG index, local IgG synthesis and AI
There was no significant change of the mean IgG index,
local IgG synthesis or AI for any of the viral antigens inves-
tigated over time (p = 0.414 for IgG index, p = 0.578 for
local IgG synthesis, p = 0.673 for measles AI, p = 0.984 for
rubella AI, p = 0.941 for varicella zoster AI, Friedman test).
The data are summarized in Table 1. In addition, there
was no significant change in the mean cell count (p =
0.291, Friedman test, data not shown).
OCB and AI positive patients
As expected, the presence of OCB in the CSF was more
sensitive in the detection of an intrathecal IgG production
than a positive IgG index [22,23]. For instance, at the 1st
LP 94% of patients had positive oligoclonal CSF bands
whereas 88% of patients had a positive IgG index. Once
positive the OCB bands remained positive during the fol-
low-up. The percentage of patients who were positive for
oligoclonal bands in the CSF increased after the 1st LP
from 94 to 100 %. Likewise, the relative number of
patients with an intrathecal antibody synthesis against
measles virus increased significantly over time (Figure 1).
No obvious change in rubella and varicella zoster anti-
body positive patients over time was observed. This signif-
icant increase in patients with an intrathecal antibody
production against measles was seen in both patient sub-
groups irrespective of whether or not they were treated
with any immunomodulatory treatment mentioned
above at the 2nd LP or not (Table 2).
Individual long-term follow-up studies
In 7 patients, data from 5 consecutive spinal taps were
available. Except for patient no. 57, all data were derived
from patients with a secondary progressive course of the
disease and collected over a period of 1 to 6 years.
Although the AI for the various antigens was not identical,
4 of the patients were stable over time with regard to their
status as antibody producers (patients no. 16, 21, 41, 52).
Of these patients, one was positive for measles alone, one
for measles and rubella, one for all three viral antigens
and one patient was antibody negative. The introduction
of an immunomodulatory or immunosuppressive treat-
ment at the 2nd LP (interferon beta patients 16, 21 and 41,
azathioprine patient no. 52) had no impact on the anti-
body production. Two additional patients experienced an
expansion of their antibody response from one (rubella
virus in both cases) to three antigens, despite treatment
initiated at the 2nd LP (interferon beta in patient no. 5 and
azathioprin in patient no. 34).
Table 1: Mean and SD of IgG index, local IgG synthesis (Igloc) and antibody index (AI) for measles, rubella and varicella zoster virus at 
each successive lumbar puncture (LP). The number of patients in each category of serial LP is given. All included patients received at 
least two serial LPs (first and second). Additional LPs were only obtained in the mentioned number of patients.
LP no. No. of patients 
with the 
respective LP
IgG index Igloc (mg/L) AI measles AI rubella AI varicella zoster
1. 70 1.3 ± 0.75 33 ± 5,0 3.4 ± 3.29 4.6 ± 7.11 3.6 ± 5.86
2. 70 1.3 ± 1.58 25 ± 4,1 3.5 ± 3.67 4.8 ± 7.67 3.6 ± 5.85
3. 26 1.4 ± 0.99 46 ± 1,1 3.9 ± 5.59 5.4 ± 9.28 4.7 ± 7.28
4. 12 1.2 ± 0.73 28 ± 0,9 2.8 ± 2.09 6.7 ± 14.78 4.4 ± 8.74
5. 7 1.0 ± 0.39 19 ± 4,8 2.1 ± 0.89 1.9 ± 1.28 1.9 ± 1.46Cerebrospinal Fluid Research 2005, 2:3 http://www.cerebrospinalfluidresearch.com/content/2/1/3
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Correlation with clinical features
There was no significant difference in the mean AI against
measles in patients with high or low disability (p = 0.995,
Mann Whitney U test) at the 1st LP. High disability was
defined as an EDSS score above the median of 3.0. Fur-
thermore, there was no difference in the mean measles AI
in patients with long and short disease duration (median
2 years, p = 0.304). The EDSS scale and disease duration
Percentage of patients with an intrathecal antibody synthesis against measles, rubella, and varicella zoster virus at five succes- sive spinal taps (LP, n = 70 for LP 1 and 2, n = 26 for LP 3, n = 12 for LP4 and n = 7 for LP5) Figure 1
Percentage of patients with an intrathecal antibody synthesis against measles, rubella, and varicella zoster virus at five succes-
sive spinal taps (LP, n = 70 for LP 1 and 2, n = 26 for LP 3, n = 12 for LP4 and n = 7 for LP5). There was a significant increase 
(p <0.05) in patients positive for antibody synthesis against measles virus over time. There were no significant changes in 
rubella or varicella zoster antibody synthesis.
Table 2: Percentage of patients who had oligoclonal bands in the CSF or a positive AI for measles at the respective lumbar puncture 
(LP).
1st LP 2nd LP p value
Untreated patients OCB 96 100 not done
measles AI 68 73 0.013
Treated patients OCB 91 100 not done
Measles AI 55 68 0.001
All patients OCB 94 100 not done
Measles AI 64 71 <0.001
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was used to calculate the progression index for each
patient. A progression index of more than 1 (median),
indicating an increase of at least 1 point on the EDSS scale
per year was regarded as high. The mean AI against mea-
sles was significantly higher in patients with a high pro-
gression index than in those with a low progression index
(p = 0.038). In the subgroup with a high progression
index the mean measles AI was 4.2, whereas in the low
progression index group a mean measles AI of 2.6 was
measured. In the low progression index subgroup 53% of
patients had an intrathecal antibody production against
measles, but almost 74% were positive for measles in the
high progression index subgroup. There were no signifi-
cant differences in the local IgG synthesis when
comparing the groups with high or low disability at the 1st
LP or the groups with a high or low progression index (p
= 0.71, p = 0.962, respectively). In these respective groups,
the IgG index was not changed (p = 0.165 high disability
group; p = 0.828 high progression index).
Discussion
There are three main findings of our study: i) Once an
intrathecal antibody production is established it is main-
tained over time; ii) For the first time we provide evidence
for an expansion of antibody reactivity in the CSF of MS
patients; and iii) disease progression and B cell activation
may be linked.
Persistent IgG production
In our study patients positive for oligoclonal IgG bands in
the CSF remained positive at the follow-up. These find-
ings are in accordance with previous data indicating a
clonally stable IgG production in the CSF over long peri-
ods [24]. This was true despite the introduction of immu-
nomodulatory or immunosuppressive treatment. In 132
MS patients serial CSF analysis before and after 2 years of
interferon beta treatment or placebo failed to reveal differ-
ences in the IgG index or OCB in either treatment group
[25]. Even after autologous hematopoietic stem cell trans-
plantation identical OCB compared to pre-treatment CSF
analysis were found [26,27]. Similarly in our study, there
was no effect of treatment on IgG production as docu-
mented by the IgG index or on the local IgG synthesis in
the CSF. In addition to the well-known finding of a stable
OCB production, we demonstrated for the first time that
the intrathecal antibody production is stable over time as
well. This means, once an intrathecal antibody response
against measles, rubella or varizella zoster virus was estab-
lished it persisted at the follow-up analyses for at least 4
years.
Although persistent IgG and antibody production is a
well-known phenomenon in multiple sclerosis, the mech-
anisms remain unknown. It has been demonstrated
recently in an experimental model of B cell migration over
the blood brain barrier that activated human B cells read-
ily cross the blood brain barrier with the help of adhesion
molecules and chemokines [5]. Longevity of B cells and
plasma cells is a common feature [28], and the microen-
vironment of MS lesions promotes the persistence and
activation of B cells [29]. Although repeated antigenic
stimulation favors longevity of B cells, persistance of anti-
gen is not required for the survival of B cells [30]. Instead,
high expression of anti-apoptotic proteins may be
involved in the survival of B cells. Interestingly, increased
expression of the apoptosis-inhibitory proteins Bcl-2 and
FLIP were detected in B cells of MS patients [6]. Allto-
gether, microenvironment and antiapoptotic signaling
might explain in part the persisting IgG and antibody
production in the CSF of MS patients even in the absence
of persistent antigen exposure.
Expansion of antigen response
More intriguing was the finding that the number of
patients positive for intrathecal OCB increased over time
from 94 to 100%. It has been assumed that in early dis-
ease activated B cells might not yet have become resident
in the CNS. Progression from a monoclonal to an oligo-
clonal CSF pattern has been reported in multiple sclerosis
patients [31]. An increase in CNS clones after the initial
stage of the disease has been suggested as a possible expla-
nation. Further evidence for an expanding B cell activity
during the course of the disease comes from a CSF analysis
in which the prevalence of mature plasma cells was found
to be higher in patients with longer disease duration [32].
In our study, an increasing number of patients showed a
newly established intrathecal antibody response against
measles virus: whereas 64% of patients were positive for
measles at the 1st LP, 71% became positive at the 2nd and
86% at the 5th LP. Furthermore, in two out of seven
patients with repeated CSF analysis, there was an expan-
sion of the B cell response from one to three viral antigens
by the 5th LP. To our knowledge, this is the first follow-up
report on intrathecal polyspecific antibody production in
multiple sclerosis patients. This follow-up for the first
time provides evidence for an expansion of antibody reac-
tivity over time in multiple sclerosis patients. However,
this expansion of antibody is in contrast to the stable local
IgG synthesis over time.
One possible explanation for a polyspecific intrathecal
antibody production might be a bystander activation of B
cells with a given antibody reactivity. This is possible in
the presence or absence of T cells. If certain cytokines -
namely tumor necrosis factor alpha- is present, IgG secre-
tion by activated B cells may occur even in the absence of
T cells [33]. Why preferentially measles, rubella, varicella
zoster and to a lesser extent other virus reactive B cellsCerebrospinal Fluid Research 2005, 2:3 http://www.cerebrospinalfluidresearch.com/content/2/1/3
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become activated during the disease process remains
unclear.
Association between B cell activity and clinical aspects of 
MS
Although the evidence of B cell activity in the CNS is a
common feature in MS, its clinical significance remains to
be elucidated. Early studies on fluctuations in the CSF
antibody production failed to show an association
between antibody titers and the clinical course, possibly
due to methodological shortcomings [17,18]. In contrast,
a recent publication revealed an association between a
very high IgG index and a rapidly progressing course of
the disease [34]. Further evidence for an impact of B cell
products on disease severity comes from a publication by
Villar and colleague. They found an intrathecal IgM syn-
thesis to be associated with a worse clinical outcome [35].
Accordingly, a predominance of B cells over T cells and
macrophages in the CSF has been shown to be associated
with a more rapid disease progression, but not with a
longer disease duration or a higher disability score [36].
Interestingly, when our patients were divided into two
subgroups according to the rate of disease progression,
there were more measles positive patients in the rapidly
progressive subgroup. Furthermore, the AI for measles
was significantly higher in those with a rapid progression
of disability.
Conclusion
In summary, our data indicate that once an intrathecal
antibody production has been established it is stable over
time. Furthermore, an expansion in antibody specifity
occurred in a proportion of patients. The presented data
support the hypothesis that a strong B cell activation is
associated with a worse clinical outcome in MS.
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